NYSE:CHE Chemed - CHE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemed Co. Please log in to your account or sign up in order to add this asset to your watchlist. $537.75 +10.44 (+1.98%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$529.39▼$538.7550-Day Range$493.18▼$537.7552-Week Range$430.16▼$539.13Volume99,545 shsAverage Volume70,990 shsMarket Capitalization$8.04 billionP/E Ratio32.53Dividend Yield0.28%Price Target$587.00 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Chemed MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside9.2% Upside$587.00 Price TargetShort InterestHealthy2.97% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-0.33Upright™ Environmental ScoreNews Sentiment0.16Based on 4 Articles This WeekInsider TradingSelling Shares$4.69 M Sold Last QuarterProj. Earnings Growth8.39%From $20.85 to $22.60 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.60 out of 5 starsMedical Sector101st out of 996 stocksHome Health Care Services Industry4th out of 9 stocks 1.5 Analyst's Opinion Consensus RatingChemed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $587.00, Chemed has a forecasted upside of 9.2% from its current price of $537.75.Amount of Analyst CoverageChemed has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.97% of the float of Chemed has been sold short.Short Interest Ratio / Days to CoverChemed has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Chemed has recently decreased by 15.57%, indicating that investor sentiment is improving significantly. Previous Next 3.3 Dividend Strength Dividend YieldChemed has a dividend yield of 0.29%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthChemed has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Chemed is 9.20%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Chemed will have a dividend payout ratio of 6.73% next year. This indicates that Chemed will be able to sustain or increase its dividend. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChemed has received a 80.32% net impact score from Upright. Chemed seems to create the most significant positive value in categories "Taxes", "Jobs", and "Meaning & joy". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private home care for the elderly", and "Property water damage restoration" products. See details.Environmental SustainabilityThe Environmental Impact score for Chemed is -0.33. Previous Next 1.8 News and Social Media Coverage News SentimentChemed has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Chemed this week, compared to 3 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chemed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,686,450.00 in company stock.Percentage Held by InsidersOnly 4.03% of the stock of Chemed is held by insiders.Percentage Held by Institutions91.12% of the stock of Chemed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Chemed are expected to grow by 8.39% in the coming year, from $20.85 to $22.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemed is 32.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemed is 32.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 127.63.Price to Earnings Growth RatioChemed has a PEG Ratio of 2.86. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioChemed has a P/B Ratio of 10.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Chemed (NYSE:CHE) StockChemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.Read More Receive CHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemed and its competitors with MarketBeat's FREE daily newsletter. Email Address CHE Stock News HeadlinesMarch 30, 2023 | americanbankingnews.comChemed Co. (NYSE:CHE) CEO Kevin J. Mcnamara Sells 3,000 SharesMarch 29, 2023 | marketwatch.comPre-Need Death Care Market Outlook and Forecast till 2028April 2, 2023 | Investorplace Media (Ad)This Tech Stock Could be the Next AmazonYou can learn its name in Luke Lango’s latest report, 5 Hypergrowth Stocks for 2023. Claim Your Free Report Here. March 24, 2023 | finance.yahoo.comZacks Industry Outlook Highlights Chemed, Addus HomeCare, RadNet and The Pennant GroupMarch 24, 2023 | americanbankingnews.comInsider Selling: Chemed Co. (NYSE:CHE) CFO Sells $2,093,000.00 in StockMarch 15, 2023 | finance.yahoo.comIs Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?March 1, 2023 | finance.yahoo.comChemed Corporation to Present at the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 25, 2023 | finance.yahoo.comChemed Full Year 2022 Earnings: EPS Misses ExpectationsApril 2, 2023 | Investorplace Media (Ad)This Tech Stock Could be the Next AmazonYou can learn its name in Luke Lango’s latest report, 5 Hypergrowth Stocks for 2023. Claim Your Free Report Here. February 25, 2023 | finance.yahoo.comQ4 2022 Chemed Corp Earnings CallFebruary 23, 2023 | finance.yahoo.comChemed (CHE) Tops Q4 Earnings and Revenue EstimatesFebruary 23, 2023 | finance.yahoo.comChemed Reports Fourth-Quarter 2022 ResultsFebruary 22, 2023 | seekingalpha.comChemed Q4 2022 Earnings PreviewFebruary 13, 2023 | marketwatch.comDeath Care Market Share 2023, International Trend and business Analysis By Applications and Leading firms, Forecast 2029February 11, 2023 | finance.yahoo.comInvestors in Chemed (NYSE:CHE) have made a respectable return of 100% over the past five yearsFebruary 9, 2023 | finance.yahoo.comChemed To Report Fourth-Quarter 2022 Earnings February 23, Related Conference Call To Be Held On February 24January 21, 2023 | finance.yahoo.comThis Low-Key Stock Jumped Nearly 600% Over the Last DecadeJanuary 13, 2023 | marketwatch.comDeath Care Market Regional Outlook & Size Projections with SWOT Analysis to Witness Rapid Growth 2028January 13, 2023 | marketwatch.comPre-Need Death Care Market : Analysis by Size, Share Trends, Future Growth, Emerging Trends, Qualitative Outlook and Global Forecast to 2028January 13, 2023 | marketwatch.comDeath Care Market 2022 to 2028 by Key Players Service Corporation International, Batesville, Chemed Corp., Matthews International CorporationDecember 27, 2022 | finance.yahoo.comChemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive ReturnsDecember 23, 2022 | msn.comThree Stock Lunch: CHEMED, Pool Corp. and Fidelity NationalDecember 23, 2022 | finance.yahoo.comChemed Corporation (CHE) Stock Historical Prices & Data - Yahoo FinanceNovember 29, 2022 | finance.yahoo.comChemed Corporation to Present at the BofA Securities 2022 Virtual Home Care ConferenceNovember 21, 2022 | finance.yahoo.comIs Chemed Corporation's (NYSE:CHE) Recent Stock Performance Tethered To Its Strong Fundamentals?November 8, 2022 | finance.yahoo.comPNTG vs. CHE: Which Stock Is the Better Value Option?November 3, 2022 | finance.yahoo.comChemed (CHE) Q3 Earnings Surpass Estimates, EPS View UpSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemed and its competitors with MarketBeat's FREE daily newsletter. Email Address CHE Company Calendar Last Earnings2/24/2023Ex-Dividend for 3/17 Dividend2/24/2023Dividend Payable3/17/2023Today4/02/2023Next Earnings (Estimated)4/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:CHE CUSIP16359R10 CIK19584 Webwww.chemed.com Phone(513) 762-6690Fax513-762-6590Employees14,167Year Founded1970Price Target and Rating Average Stock Price Forecast$587.00 High Stock Price Forecast$587.00 Low Stock Price Forecast$587.00 Forecasted Upside/Downside+9.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$16.53 Trailing P/E Ratio32.53 Forward P/E Ratio25.79 P/E Growth2.86Net Income$249.62 million Net Margins11.69% Pretax Margin15.44% Return on Equity41.54% Return on Assets22.02% Debt Debt-to-Equity Ratio0.12 Current Ratio0.92 Quick Ratio0.88 Sales & Book Value Annual Sales$2.13 billion Price / Sales3.77 Cash Flow$24.62 per share Price / Cash Flow21.84 Book Value$53.71 per share Price / Book10.01Miscellaneous Outstanding Shares14,948,000Free Float14,346,000Market Cap$8.04 billion OptionableOptionable Beta0.52 Social Links Key ExecutivesKevin J. McNamaraPresident, Chief Executive Officer & DirectorDavid Patrick WilliamsChief Financial Officer & Executive Vice PresidentSpencer S. LeeExecutive Vice PresidentNicholas M. WestfallExecutive Vice PresidentThomas C. HuttonDirector & Vice PresidentKey CompetitorsAmedisysNASDAQ:AMEDSignify HealthNYSE:SGFYOption Care HealthNASDAQ:OPCHShockwave MedicalNASDAQ:SWAVDENTSPLY SIRONANASDAQ:XRAYView All CompetitorsInsiders & InstitutionsKevin J McnamaraSold 3,000 sharesTotal: $1.58 M ($526.27/share)Acrisure Capital Management LLCBought 1,086 shares on 3/28/2023Ownership: 0.007%David Patrick WilliamsSold 4,000 sharesTotal: $2.09 M ($523.25/share)Kevin J McnamaraSold 2,000 sharesTotal: $1.01 M ($507.32/share)Capital Asset Advisory Services LLCSold 518 shares on 3/8/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions CHE Stock - Frequently Asked Questions Should I buy or sell Chemed stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CHE shares. View CHE analyst ratings or view top-rated stocks. What is Chemed's stock price forecast for 2023? 1 brokers have issued 12-month price objectives for Chemed's stock. Their CHE share price forecasts range from $587.00 to $587.00. On average, they anticipate the company's share price to reach $587.00 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price. View analysts price targets for CHE or view top-rated stocks among Wall Street analysts. How have CHE shares performed in 2023? Chemed's stock was trading at $510.43 at the beginning of the year. Since then, CHE shares have increased by 5.4% and is now trading at $537.75. View the best growth stocks for 2023 here. Are investors shorting Chemed? Chemed saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 432,300 shares, a drop of 15.6% from the February 28th total of 512,000 shares. Based on an average trading volume of 73,600 shares, the short-interest ratio is currently 5.9 days. Currently, 3.0% of the company's shares are sold short. View Chemed's Short Interest. When is Chemed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023. View our CHE earnings forecast. How were Chemed's earnings last quarter? Chemed Co. (NYSE:CHE) issued its earnings results on Friday, February, 24th. The company reported $5.39 EPS for the quarter, topping the consensus estimate of $5.30 by $0.09. The company earned $546.65 million during the quarter, compared to analysts' expectations of $546.60 million. Chemed had a trailing twelve-month return on equity of 41.54% and a net margin of 11.69%. Chemed's revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.25 earnings per share. How often does Chemed pay dividends? What is the dividend yield for Chemed? Chemed declared a quarterly dividend on Friday, February 17th. Stockholders of record on Monday, February 27th will be paid a dividend of $0.38 per share on Friday, March 17th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Friday, February 24th. Read our dividend analysis for CHE. What ETFs hold Chemed's stock? ETFs with the largest weight of Chemed (NYSE:CHE) stock in their portfolio include VictoryShares THB Mid Cap ESG ETF (MDCP), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ), First Trust Dorsey Wright Momentum & Low Volatility ETF (DVOL), Inspire Faithward Mid Cap Momentum ETF (GLRY), Opus Small Cap Value Plus ETF (OSCV), Dividend Performers ETF (IPDP), FIS Biblically Responsible Risk Managed ETF (PRAY) and Natixis Vaughan Nelson Select ETF (VNSE). Is Chemed a good dividend stock? Chemed (NYSE:CHE) pays an annual dividend of $1.52 per share and currently has a dividend yield of 0.29%. The company has been increasing its dividend for 14 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 9.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHE will have a dividend payout ratio of 6.73% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for CHE. What guidance has Chemed issued on next quarter's earnings? Chemed updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of $20.75-$21.10 for the period, compared to the consensus EPS estimate of $20.21. The company issued revenue guidance of $2.24 billion-$2.25 billion, compared to the consensus revenue estimate of $2.21 billion. What is Kevin J. McNamara's approval rating as Chemed's CEO? 1 employees have rated Chemed Chief Executive Officer Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among the company's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Chemed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX). What is Chemed's stock symbol? Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE." How do I buy shares of Chemed? Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Chemed's stock price today? One share of CHE stock can currently be purchased for approximately $537.75. How much money does Chemed make? Chemed (NYSE:CHE) has a market capitalization of $8.04 billion and generates $2.13 billion in revenue each year. The company earns $249.62 million in net income (profit) each year or $16.53 on an earnings per share basis. How many employees does Chemed have? The company employs 14,167 workers across the globe. How can I contact Chemed? Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The official website for the company is www.chemed.com. The company can be reached via phone at (513) 762-6690 or via fax at 513-762-6590. This page (NYSE:CHE) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.